Testing a faster tuberculosis treatment for drug-resistant cases

This trial is testing a new ultra-short treatment plan for tuberculosis that uses four medications together: bedaquiline, linezolid, sitafloxacin, and pyrazinamide. The goal is to cure tuberculosis much faster than current treatments—in just 2 to 3 months instead of 4 to 6 months—while working for both drug-sensitive and drug-resistant forms of the disease. This treatment is designed to be simpler, more affordable, and easier for patients to stick with.

Tuberculosis remains a serious global health threat, and drug-resistant forms are becoming more common and harder to treat. This medication aims to solve two major problems: reducing treatment time so patients don't have to take drugs for months on end, and creating one universal regimen that works against all forms of TB rather than needing different treatments for different types.